Claudio Anasetti

Moffitt Cancer Center — United States

Medicine · Health Sciences

107h-index41.0kcitations851works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(503), T-cell and B-cell Immunology(185), Immune Cell Function and Interaction(152), Acute Lymphoblastic Leukemia research(143), Acute Myeloid Leukemia Research(114)

Publications851 total

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia
Transplantation and Cellular Therapy·2025
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide
Bone Marrow Transplantation·2025
Phase <scp>II</scp> Trial of Reduced‐Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant
American Journal of Hematology·2025Open Access
CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease
JCO oncology advances.·2025· 1 citedOpen Access
Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
Transplantation and Cellular Therapy·2025
Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients
Cancers·2025Open Access
Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Blood·2024
Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
Blood·2024
Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
Blood·2024
Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
Blood·2024
Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
Blood·2024Open Access
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Transplantation and Cellular Therapy·2024· 5 cited
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
Transplantation and Cellular Therapy·2024· 4 cited
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results
Blood·2024· 3 citedOpen Access
Mismatched donor allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
American Journal of Hematology·2024Open Access
Expanded Antigen-Specific Donor Regulatory T Cells for Gvhd Prevention
Transplantation and Cellular Therapy·2024
JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results
Transplantation and Cellular Therapy·2024
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
Transplantation and Cellular Therapy·2024
Supplementary Figure S1 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
2023Open Access
Supplementary Table S1 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
2023Open Access
page 1 of 43Next →

Frequent Co-authors

Rainer Storb(19), Effie W. Petersdorf(15), Paul J. Martin(12), H. Joachim Deeg(12), John A. Hansen(11), CD Buckner(10), Jean E. Sanders(10), K Doney(10), FR Appelbaum(9), Jack W. Singer(9), Thomas R. Chauncey(8), Ann E. Woolfrey(7), Barry E. Storer(7), Frederick R. Appelbaum(6), Eileen Bryant(6), John T. Slattery(6), Dennis L. Confer(5), Mary Eapen(5), Mary M. Horowitz(5), Stephen R. Spellman(5)